Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
1 In May 2022, Tirzepatide, the world's first GLP-1R/GIPR dual-target agonist, was approved for marketing
Many effective products combine both ingredients for enhanced results
your prescriber will advise based on your body composition
"Pregnancy or intention to become pregnant were exclusion criteria in our trials with semaglutide in both obesity and type 2 diabetes
Fiber-rich and nutrient-dense Whole foods like vegetables, legumes, and healthy fats help keep digestion smooth and support gut health both important on a GLP-1 journey